TB-500 cleared the FDA’s compounding advisory committee on the same 8–6 split as BPC-157. The more interesting story is the objection it cleared over — because that objection is the single best argument for scrutinizing your supplier.
Where TB-500 landed
On Day 1 of the July 23–24 meeting, the Pharmacy Compounding Advisory Committee recommended BPC-157, KPV, and TB-500 for the 503A Bulk Drug Substances List, each by a vote of eight in favor, six opposed, with one abstention. MOTS-c followed at 7–5 with two abstentions. Four for four on the day, against a staff briefing that had recommended against all of them.
The votes covered free base and acetate formulations separately — a procedural detail that matters more than it sounds, because it is the committee acknowledging that “TB-500” is not one thing.
The identity problem
FDA reviewers’ central objection across the whole docket was chemical characterization. In plain terms: if the field cannot agree on exactly what molecule a name refers to, then identity, quality, and lot-to-lot comparability are unresolvable, and every downstream safety or effectiveness claim inherits that uncertainty.
TB-500 is the clearest example on the docket. It circulates as a synthetic fragment associated with the active region of Thymosin Beta-4, not as the intact parent peptide, and supplier practice is not uniform. Two vendors can print the same three characters and a number on a label and ship materially different material.
The regulatory fight is about whether a pharmacy can be held to a defined standard. Until that is settled, the only standard available to a research buyer is the supplier’s own third-party analysis — and specifically, analysis tied to the lot number printed on the vial you received, not a generic PDF for the product line.
The full Day 1 scorecard
| Compound | Vote | Result |
|---|---|---|
| BPC-157 | 8–6–1 | Recommended |
| KPV | 8–6–1 | Recommended |
| TB-500 | 8–6–1 | Recommended |
| MOTS-c | 7–5–2 | Recommended |
What does not change
Three things are worth stating plainly, because the post-vote commentary blurred all of them.
- No legal status changed. The recommendation initiates a rulemaking process. Legal compounding authority arrives, if it arrives, at the end of that process — commonly estimated at 8 to 24 months.
- No efficacy finding occurred. The 503A question is about compounding eligibility. Committee dissenters explicitly warned that the public would read a yes vote as endorsement. They were right within about six hours.
- Anti-doping status is untouched. TB-500 remains prohibited in tested sport. FDA compounding policy and WADA prohibited lists are separate systems that do not talk to each other.
Sourcing in the interim
For research applications, the practical question is unchanged: which suppliers publish per-lot third-party testing, and will they send you the certificate for your specific lot if you ask. The ones that hesitate have answered the question.
TB-500 research suppliers
Frequently Asked
Eight in favor, six opposed, one abstention — the same margin as BPC-157 and KPV. All three lead compounds cleared on an identical split on Day 1.
Not exactly, and the distinction is part of why FDA reviewers objected. TB-500 is commonly sold as a synthetic fragment related to the active region of Thymosin Beta-4 rather than the full 43-amino-acid parent peptide. Different suppliers do not always mean the same molecule when they print the same name on a vial.
No. The recommendation initiates rulemaking; it does not create a prescribing pathway. Until the FDA completes notice-and-comment rulemaking, 503A pharmacies have no unambiguous authority to compound it.
Yes. TB-500 remains a prohibited substance under anti-doping rules regardless of what the FDA does with compounding eligibility. Tested athletes should treat the PCAC vote as irrelevant to their situation.
Because it is the FDA’s own stated objection. Without an accepted chemical definition, two vials labeled TB-500 can differ in sequence, purity, and content. A lot-specific third-party COA is the only practical way a buyer resolves that.